GoKawiilDeaths in gene-editing trials spotlight China's fast-track IIT rules under Order 818
Two children reportedly died after receiving gene-editing treatments in separate investigator-initiated trials (IITs) in China, drawing scrutiny to the country's rapid trial pathway. The deaths surfaced just months after Beijing introduced Order 818, a rule effective May 1 that tightens oversight of IITs, including restricting stem-cell and gene therapy trials to top-tier sanjia hospitals.
GoKawiil's interpretation of the reporting above, not reported fact.
IITs have fueled China's rise as a global leader in cell and gene therapy research by allowing faster, cheaper testing than the formal drug-approval process overseen by the National Medical Products Administration. These deaths raise questions about whether enforcement gaps in the previous system contributed to patient harm, and whether the new Order 818 rules will meaningfully improve safety without slowing the innovation pipeline that has made China increasingly competitive with the US.
- Two child deaths in separate gene-editing IITs have drawn scrutiny to China's fast-track trial system.
- Order 818, effective May 1, restricts advanced biomedical IITs to top-level sanjia hospitals.
- IITs have driven an 11-fold rise in China's registered cell and gene therapy trials since 2015.
Source: nature.com — You, 2026-09-08
Published there as: “China’s fast-track clinical trials are in the spotlight after child deaths”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.